Secondary mechanistic analysis of skin biopsies from the STEPIn trial: with secukinumab for up to 52 weeks, gene expression normalised in new-onset and long-standing psoriasis, but disease-associated DNA methylation persisted only in long-standing disease.
Secondary analysis
Gudjonsson et al. Early intervention with secukinumab prevents epigenetic scar development in new-onset psoriasis: STEPIn mechanistic substudy results